Last updated: February 13, 2026
Product Overview
The NDC 47781-0303 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb. It is used in oncology for conditions such as melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and various other cancers approved by the FDA.
Market Landscape
The global immuno-oncology market, driven by nivolumab, is projected to grow from $11.4 billion in 2021 to approximately $22.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% (source [1]).
Competitive Environment
Nivolumab faces competition mainly from pembrolizumab (Keytruda, Merck), atezolizumab (Tecentriq, Roche), and durvalumab (Imfinzi, AstraZeneca). These agents are approved for multiple similar indications, creating a crowded market landscape.
Pricing Dynamics
In the U.S., the list price for nivolumab ranges from $5,000 to $6,000 per 100 mg vial. The typical treatment regimen involves 240 mg every two weeks or 480 mg every four weeks, leading to average annual treatment costs of approximately $100,000 to $150,000 per patient.
Historical Price Trends:
- Post-approval, initial pricing was around $13,000 per dose (2015).
- Price reductions have resulted in current pricing levels, reflecting payer negotiations and market pressures.
- No significant price decreases observed over recent years but increased competition has kept prices relatively stable.
Market Adoption & Pricing Factors:
- Indication expansion: Continual FDA approvals for additional cancers expand potential customer base.
- Pricing negotiations: Payers exert pressure to reduce prices, especially as biosimilars and competing agents penetrate the market.
- Reimbursement policies: CMS and private insurers influence net prices via formularies and coverage restrictions.
Pricing Projections:
- Short-term (1-2 years): Prices remain stable within current ranges but may face slight downward pressure (~5%) due to increased payer negotiations.
- Mid-term (3-5 years): Potential for modest price reductions (~10%) driven by new biosimilar products, though no biosimilars for nivolumab have entered the U.S. market as of 2023.
- Long-term (5+ years): Price declines could reach 20-25% if biosimilars or generics gain approval and market share.
Regulatory and Policy Impact
- Biosimilar pathway offers a potential $1 billion market entry by 2028 (source [2]).
- Changes in Medicare and Medicaid reimbursement policies may influence net prices.
- International prices are generally lower, with countries like Canada and European nations paying 30-50% less than U.S. prices.
Market Entry Barriers
- Patent protections extend into late 2020s, delaying biosimilar competition.
- Extensive clinical trials and regulatory pathways designed to safeguard expensive biologics from generic competition.
Summary of Price Projections
| Timeframe |
Expected Price Trend |
Approximate Change |
| 2023-2024 |
Stable at current levels |
No significant change |
| 2024-2026 |
Slight reduction due to payer negotiations |
-5 to -10% |
| 2026-2028 |
Increased biosimilar competition, potential price drops |
-10 to -20% |
| 2028+ |
Biosimilar market penetration potentially drives greater price erosion |
Up to -25% at peak |
Key Takeaways
- Nivolumab remains a high-price biologic with annual treatment costs exceeding $100,000 in the U.S.
- Market growth driven by expanding indications and increasing adoption across oncology segments.
- Price stability expected short-term, with gradual declines possible as biosimilar competition develops.
- International pricing remains significantly lower, influencing global revenue strategies.
- Regulatory and patent landscapes are critical factors in future pricing and market access.
FAQs
-
When will biosimilars for nivolumab enter the U.S. market?
No biosimilars for nivolumab have received FDA approval as of 2023; biosimilar pathway applications are under review, with potential approval in the late 2020s.
-
What are the main factors affecting nivolumab prices?
Competition from other immune checkpoint inhibitors, biosimilar entry, payer negotiations, and regulatory policies.
-
How does international pricing compare to U.S. prices?
International prices are approximately 30-50% lower, influenced by healthcare systems' negotiation power and pricing regulations.
-
What is the expected pipeline impact on nivolumab pricing?
Expanded indications and biosimilar competition are key factors; long-term, these could reduce prices by up to 25%.
-
Are there current efforts to reduce nivolumab costs?
Payer negotiations and patent expirations are gradually pressuring prices downward; biosimilar development is ongoing.
References
[1] MarketWatch, "Immuno-Oncology Market Forecast," 2022.
[2] IQVIA, "Biologics and Biosimilars Market Outlook," 2023.
